Pennant Group (PNTG) Aktievy
The Pennant Group, Inc. tillhandahåller sjukvårdstjänster i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 3/6 |
| Finansiell hälsa | 3/6 |
| Utdelningar | 0/6 |
PNTG Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Pennant Group, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$33.45 |
| 52 veckors högsta | US$37.54 |
| 52 veckors lägsta | US$21.73 |
| Beta | 1.27 |
| 1 månads förändring | -4.37% |
| 3 månaders förändring | 7.73% |
| 1 års förändring | 19.21% |
| 3 års förändring | 167.60% |
| 5 års förändring | -20.98% |
| Förändring sedan börsintroduktionen | 121.67% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 04
PNTG: Senior Living Expansion And Higher P/E Assumptions Will Support Future Upside Potential
Narrative Update on Pennant Group The analyst fair value estimate for Pennant Group has moved from $36.00 to $40.00, with analysts pointing to updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers for the new price targets. Analyst Commentary Recent Street research around Pennant Group has centered on updated price targets that reflect revised assumptions for revenue, profitability, and the P/E multiple applied to future earnings.Uppdatering av berättelse • May 06
PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential
Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.Recent updates
Uppdatering av berättelse • Jun 04
PNTG: Senior Living Expansion And Higher P/E Assumptions Will Support Future Upside Potential
Narrative Update on Pennant Group The analyst fair value estimate for Pennant Group has moved from $36.00 to $40.00, with analysts pointing to updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers for the new price targets. Analyst Commentary Recent Street research around Pennant Group has centered on updated price targets that reflect revised assumptions for revenue, profitability, and the P/E multiple applied to future earnings.Uppdatering av berättelse • May 06
PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential
Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.
Uppdatering av berättelse • Apr 22
PNTG: AMED Assets Are Expected To Underpin Future Upside Despite 2026 Guidance
Narrative Update Analysts have nudged Pennant Group's price target higher, with recent moves such as RBC Capital's increase to $41 from $39 contributing to a modest lift in estimated fair value and future P/E assumptions. Analyst Commentary Recent Street research around Pennant Group centers on how the market should weigh its guidance against longer term earnings potential from AMED assets and what that could imply for valuation.Uppdatering av berättelse • Apr 07
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Guidance
Narrative Update on Pennant Group Analysts have lifted Pennant Group's price targets into a $38 to $41 range, citing long-term earnings potential tied to AMED assets. They also hold a relatively favorable view of Medicare Advantage exposure, even with mixed near term guidance and sector headwinds.Uppdatering av berättelse • Mar 24
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Outlook
Narrative Update Analysts have recently nudged Pennant Group's average price target higher into the high $30s to low $40s range, citing confidence that the company can gradually realize earnings potential from the AMED assets, even though 2026 adjusted EBITDA guidance sits below earlier expectations. Analyst Commentary Recent research updates show analysts adjusting expectations for Pennant Group while still assigning higher price targets.Uppdatering av berättelse • Mar 10
PNTG: AMED Earnings Potential Will Offset Tempered Outlook For 2026
Pennant Group's updated fair value estimate edges up to about $37.83 from $37.50 as analysts lift price targets into the high $30s and low $40s, pointing to confidence in long term earnings potential from AMED assets, despite more tempered revenue growth assumptions and a slightly lower future P/E multiple. Analyst Commentary Recent research points to a generally constructive view on Pennant Group, with price targets shifting into the high $30s and low $40s range.Uppdatering av berättelse • Feb 24
PNTG: Fair Outlook Will Weigh Medicare Advantage Constructiveness Against Policy And Margin Risks
Analysts have raised their price target on Pennant Group from $31 to $38, with the higher fair value of $34 linked to updated views on revenue growth, profit margin, and a higher future P/E multiple in the context of a relatively constructive stance on Medicare Advantage. Analyst Commentary Even with the higher price target range and a constructive stance on Medicare Advantage, some commentary around Pennant Group points to risks that are worth keeping in mind as you weigh the setup.Uppdatering av berättelse • Feb 10
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Narrative Update on Pennant Group Analysts have raised their price target on Pennant Group to $38 from $31, citing potential upside from home health reimbursement rates even under conservative assumptions, and noting that recent regulatory concerns are already reflected in the shares. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the shares even when they assume conservative home health reimbursement rates, which they view as already reflected in the current valuation.Analysartikel • Jan 28
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Uppdatering av berättelse • Jan 26
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Analysts have lifted their price target on Pennant Group to US$38 from US$31, citing potential upside from home health reimbursement rates even under conservative assumptions. They also view the current valuation as offering attractive optionality if reimbursement trends improve.Uppdatering av berättelse • Jan 11
PNTG: Raised Fair Value Framework Will Rely On Home Health Reimbursement Outcomes
Analysts have raised their price target on Pennant Group from $31 to $38, citing updated fair value assumptions of $37.50, a higher future P/E estimate of 27.33, and expectations for stronger revenue growth, while also accounting for a slightly higher discount rate and a modestly lower profit margin outlook. Analyst Commentary Recent Street research provides a mix of optimism and caution around Pennant Group, with updated targets and ratings reflecting changing views on reimbursement, valuation, and sector risk.Uppdatering av berättelse • Dec 16
PNTG Will Balance Reimbursement Upside Against Policy And Margin Execution Risks
Pennant Group's analyst price target has been raised from $28 to $30 per share, as analysts highlight upside from potential home health reimbursement improvements despite conservative base case assumptions. Analyst Commentary While the latest target increase underscores growing optimism around home health reimbursement, not all market observers share an unequivocally bullish stance.Analysartikel • Aug 09
The Pennant Group, Inc. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
NasdaqGS:PNTG 1 Year Share Price vs Fair Value Explore Pennant Group's Fair Values from the Community and select yours...Analysartikel • Jul 17
Earnings Tell The Story For The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 32.2x might make it look like a strong...Analysartikel • Jun 28
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • May 16
Pennant Group's (NASDAQ:PNTG) Earnings Are Weaker Than They Seem
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock was strong after they recently reported robust earnings. However, our...Analysartikel • Apr 15
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 33% Discount?
Key Insights Pennant Group's estimated fair value is US$38.66 based on 2 Stage Free Cash Flow to Equity Pennant Group...Analysartikel • Mar 01
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysartikel • Dec 21
Why Investors Shouldn't Be Surprised By The Pennant Group, Inc.'s (NASDAQ:PNTG) P/E
With a price-to-earnings (or "P/E") ratio of 44.5x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...Analysartikel • Nov 14
Investors Shouldn't Be Too Comfortable With Pennant Group's (NASDAQ:PNTG) Earnings
Unsurprisingly, The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock price was strong on the back of its healthy earnings...Analysartikel • Nov 12
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 34% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pennant Group fair value estimate is US$50.94 Current share...Analysartikel • Oct 06
Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Ny berättelse • Sep 16
Critical Acquisitions And Leadership Drive Remarkable Growth In Home Health Sector
Emphasis on expansion and acquisitions, such as the Muir Home Health joint venture, aims to significantly boost revenue and market share.Analysartikel • Sep 14
Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 53.9x might make it look like a strong...Analysartikel • Aug 26
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • May 14
Here's Why Pennant Group (NASDAQ:PNTG) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Mar 05
The Pennant Group, Inc. (NASDAQ:PNTG) Not Flying Under The Radar
With a price-to-earnings (or "P/E") ratio of 42.2x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...Analysartikel • Jan 06
Pennant Group (NASDAQ:PNTG) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aktieägarnas avkastning
| PNTG | US Healthcare | US Marknad | |
|---|---|---|---|
| 7D | 2.0% | -1.2% | 2.0% |
| 1Y | 19.2% | 16.8% | 23.3% |
Avkastning vs industri: PNTG översteg US Healthcare branschen som gav 16.8 % under det senaste året.
Avkastning vs Marknaden: PNTG presterade sämre än US marknaden som gav 23.3 % under det senaste året.
Prisvolatilitet
| PNTG volatility | |
|---|---|
| PNTG Average Weekly Movement | 5.9% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: PNTG har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: PNTG s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2019 | 9,700 | Brent Guerisoli | pennantgroup.com |
The Pennant Group, Inc. tillhandahåller hälsovårdstjänster i USA. Verksamheten bedrivs inom två segment, Home Health and Hospice Services och Senior Living Services. Bolaget erbjuder hemsjukvårdstjänster, inklusive kliniska tjänster såsom omvårdnad, tal-, arbets- och fysioterapi, medicinskt socialt arbete och hemtjänst, samt hospicetjänster som omfattar klinisk vård, utbildning och rådgivning för att tillgodose fysiska, andliga och psykosociala behov hos dödssjuka patienter och deras familjer.
The Pennant Group, Inc. Sammanfattning av grunderna
| PNTG grundläggande statistik | |
|---|---|
| Börsvärde | US$1.20b |
| Vinst(TTM) | US$30.32m |
| Intäkter(TTM) | US$1.02b |
38.4x
P/E-förhållande1.1x
P/S-förhållandeÄr PNTG övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| PNTG resultaträkning (TTM) | |
|---|---|
| Intäkter | US$1.02b |
| Kostnad för intäkter | US$822.28m |
| Bruttovinst | US$200.95m |
| Övriga kostnader | US$170.62m |
| Intäkter | US$30.32m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 0.87 |
| Bruttomarginal | 19.64% |
| Nettovinstmarginal | 2.96% |
| Skuld/egenkapitalförhållande | 43.6% |
Hur har PNTG utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/18 22:04 |
| Aktiekurs vid dagens slut | 2026/06/18 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
The Pennant Group, Inc. bevakas av 8 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Brian Tanquilut | Jefferies LLC |
| Michael Wiederhorn | Oppenheimer & Co. Inc. |
| Benjamin Hendrix | RBC Capital Markets |